Median PFS and OS for high-risk relapsed CLL patients after CFAR and FCR salvage therapy. (A) Median PFS for all patients with who received CFAR chemoimmunotherapy and 80 patients who received salvage FCR chemoimmunotherapy matched for age, stage, lymphocyte count, cytogenetic risk group, number of prior therapies, and prior fludarabine response. There was no significant difference in PFS between patients who received CFAR as salvage therapy compared with the matched FCR salvage patients (11 vs 15 months, P = .45). (B) Estimated median OS was longer for patients who received CFAR salvage therapy compared with matched FCR patients (17 vs 28 months, respectively, P = .048), although matching could not account for the number of patients who had received prior FCR, which was significantly higher in the CFAR salvage group. (C) PFS for high-risk relapsed patients (defined as patients with complex cytogenetics or chromosome 17 abnormalities, patients refractory to fludarabine, or patients who had received 3 or more prior treatments) who received CFAR as salvage therapy (n = 58) compared with similar patients treated with FCR as salvage therapy at M. D. Anderson Cancer Center (n = 123). There was no significant difference in PFS for these 2 groups of patients. (D) OS for high-risk relapsed CLL patients who received CFAR and FCR. Median OS was significantly shorter for patients who had received CFAR as salvage therapy.